Oakland-based nonprofit research group Curable has teamed with Mayo Clinic and a subsidiary of Regeneron Pharmaceuticals Inc. for the biggest genetic sequencing project yet for primary sclerosing cholangitis, a life-threatening disease that causes liver failure.
Regeneron Genetics Center LLC will sequence the DNA of 5,000 or more people who have PSC and also sample healthy volunteers to help identify the genetic causes of the disease. Mayo will contribute over 3,000 DNA samples from volunteers, including 1,200 samples from PSC patients.
Curable is partnering with a coalition of nonprofit institutions for the project, including Regeneron Genetics Center, which will provide sequencing and analytical capabilities.
About 50,000 people have primary sclerosing cholangitis in the United States. There is no known cure.
Mayo, in Rochester, Minn., is a “national mecca” for the disease, providing the research heft needed to identify the causes, said Curable founder Lisa Boyette.
“The first step is really building numbers,” Dr. Boyette said. “We have some ambitious plans.”
Dr. Boyette founded the nonprofit research accelerator Save Jon Inc. in 2014 after her brother, Jonathan Boyette, was diagnosed with PSC. The organization uses engineering approaches to develop medicines for rare diseases and the organization’s name was later changed to Curable.
Curable has three employees and four consultants, and the organization generated a little over $500,000 in revenue last year.
Sequencing and genetic analysis will help researchers understand the causes of PSC, which may lead the way to drug treatments, according to Aris Baras, vice president and co-head of Tarrytown, N.Y.-based Regeneron Genetics Center.
Curable is the first organization of its kind in Pittsburgh, said Dietrich Stephan, chairman of Curable’s board of directors.
“This focus on awareness, matchmaking and effectively leveraging resources to achieve transformational solutions for underserved patients is what makes Curable unique,” Mr. Stephan said in a prepared statement.
Kris B. Mamula: kmamula@post-gazette.com.






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.